Dasatinib targets multiple tyrosine kinases, including BCR-ABL, SRC family kinases, c-KIT, and PDGFR-beta. By inhibiting these proteins, dasatinib interferes with cancer cell signaling pathways, which leads to reduced proliferation and increased apoptosis of cancer cells.
